Abstract
Oncolytic virus therapy has recently been recognized as a promising new treatment option for cancer. The strategy is to use genetically engineered or naturally occurring viruses that selectively replicate in and kill cancer cells, without harming normal cells. Herpes simplex virus type 1 (HSV-1) has been well studied and has many advantages for the use in cancer therapy, making it the mainstay of current clinical trials of oncolytic virus therapy. Numerous preclinical and clinical studies of oncolytic HSV-1 have demonstrated its safety and antitumor efficacy, the latter of which is mainly attributable to its direct cytocidal effect. However, recent studies have also suggested that oncolytic HSV-1 elicits host antitumor immunity and induces immunogenic cancer cell death, thus offering possibilities for multifaceted strategies by focusing on enhancement of host anticancer immunity. In this review, we summarize the history and current status of preclinical and clinical studies of oncolytic virus therapy using HSV-1.
Keywords: Clinical trial, G47Δ, genetically engineered, herpes simplex virus, HSV-1, oncolytic virus.
Current Cancer Therapy Reviews
Title:New Generation of Oncolytic Herpes Virus
Volume: 11 Issue: 3
Author(s): Hiroshi Fukuhara and Tomoki Todo
Affiliation:
Keywords: Clinical trial, G47Δ, genetically engineered, herpes simplex virus, HSV-1, oncolytic virus.
Abstract: Oncolytic virus therapy has recently been recognized as a promising new treatment option for cancer. The strategy is to use genetically engineered or naturally occurring viruses that selectively replicate in and kill cancer cells, without harming normal cells. Herpes simplex virus type 1 (HSV-1) has been well studied and has many advantages for the use in cancer therapy, making it the mainstay of current clinical trials of oncolytic virus therapy. Numerous preclinical and clinical studies of oncolytic HSV-1 have demonstrated its safety and antitumor efficacy, the latter of which is mainly attributable to its direct cytocidal effect. However, recent studies have also suggested that oncolytic HSV-1 elicits host antitumor immunity and induces immunogenic cancer cell death, thus offering possibilities for multifaceted strategies by focusing on enhancement of host anticancer immunity. In this review, we summarize the history and current status of preclinical and clinical studies of oncolytic virus therapy using HSV-1.
Export Options
About this article
Cite this article as:
Fukuhara Hiroshi and Todo Tomoki, New Generation of Oncolytic Herpes Virus, Current Cancer Therapy Reviews 2015; 11 (3) . https://dx.doi.org/10.2174/1573394712666160128201756
DOI https://dx.doi.org/10.2174/1573394712666160128201756 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Targets of Curcumin
Current Drug Targets Ribonucleases, Nucleases and Antiangiogenins in Antiproliferative Activities
Current Signal Transduction Therapy Targeting the Immune System in Cancer
Current Pharmaceutical Biotechnology Signaling Epicenters: The Role of Caveolae and Caveolins in Volatile Anesthetic Induced Cardiac Protection
Current Pharmaceutical Design Meet Our Editorial Board Member:
Recent Patents on Anti-Infective Drug Discovery Molecular Pathogenesis of Non Muscle-Invasive Bladder Cancer: Implications for Novel Targeted Therapies
Current Molecular Medicine Mechanisms to Inhibit Matrix Metalloproteinase Activity: Where are we in the Development of Clinically Relevant Inhibitors?
Recent Patents on Anti-Cancer Drug Discovery Specific Hemosiderin Deposition in Spleen Induced by a Low Dose of Cisplatin: Altered Iron Metabolism and Its Implication as an Acute Hemosiderin Formation Model
Current Drug Metabolism Biodistribution and Safety Assessment of Bladder Cancer Specific Recombinant Oncolytic Adenovirus in Subcutaneous Xenografts Tumor Model in Nude Mice
Current Gene Therapy 7-O-aminoalkyl-2,3-dehydrosilibinins: Synthesis and in vitro Anti-cancer Efficacy
Anti-Cancer Agents in Medicinal Chemistry Neurotrophic Factors in Combination: A Possible new Therapeutic Strategy to Influence Pathophysiology of Spinal Cord Injury and Repair Mechanisms
Current Pharmaceutical Design Efficacy of Therapy with c-Met/HGF Inhibitors in Solid Tumors: A Systematic Review Based on 24 Clinical Trials
Clinical Cancer Drugs Deregulation of HOX B13 Expression in Urinary Bladder Cancer Progression
Current Medicinal Chemistry Potential Natural Dual Agonist PPARα/γ-induced Antidiabetic and Antidyslipidemic Properties of Safrole-Free Nutmeg Seed (Myristica fragrans Houtt) Extract
The Natural Products Journal Substance P: Structure, Function, and Therapeutics
Current Topics in Medicinal Chemistry Promising Protective Effects of Chrysin in Cardiometabolic Diseases
Current Drug Targets Recognition of Nucleic Acids by Toll-Like Receptors and Development of Immunomodulatory Drugs
Current Medicinal Chemistry The Therapeutic Potential of Gallium-Based Complexes in Anti-Tumor Drug Design
Letters in Drug Design & Discovery Effect of Curcumin on Pro-angiogenic Factors in the Xenograft Model of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders
Current Neuropharmacology